Epoxide hydrolase: Difference between revisions
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
== Function == | == Function == | ||
'''Epoxide hydrolase''' (EH) converts epoxides to trans-dihydrodiols which are excreted from the body. Thus, EH acts as a detoxification agent. Epoxides are formed from degradation of aromatic compounds<ref>PMID:18585390</ref>.<br /> '''Bifunctional EH 2''' or '''soluble EH''' (SEH) is a bifunctional enzyme with the C-terminal domain having EH activity and the N-terminal domain having lipid phosphatase activity.<br /> '''Limonene-1,2-epoxide hydrolase''' catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol<ref>PMID:12773375</ref> . | '''Epoxide hydrolase''' (EH) converts epoxides to trans-dihydrodiols which are excreted from the body. Thus, EH acts as a detoxification agent. Epoxides are formed from degradation of aromatic compounds<ref>PMID:18585390</ref>.<br /> '''Bifunctional EH 2''' or '''soluble EH''' (SEH) is a bifunctional enzyme with the C-terminal domain having EH activity and the N-terminal domain having lipid phosphatase activity.<br /> '''Limonene-1,2-epoxide hydrolase''' catalyzes the conversion of limonene-1,2-epoxide to limonene-1,2-diol<ref>PMID:12773375</ref> . For details see [[limonene-1,2-epoxide hydrolase]]. | ||
== Disease == | == Disease == | ||
Line 14: | Line 14: | ||
<scene name='70/708145/Cv/7'>Inhibitor binding site</scene> (PDB code [[5alf]]).<ref>PMID:25931264</ref> | <scene name='70/708145/Cv/7'>Inhibitor binding site</scene> (PDB code [[5alf]]).<ref>PMID:25931264</ref> | ||
== 3D Structures of epoxide hydrolase== | == 3D Structures of epoxide hydrolase== | ||
[[Epoxide hydrolase 3D structures]] | |||
</StructureSection> | |||
== References == | == References == | ||
<references/> | <references/> | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Latest revision as of 13:10, 31 August 2020
FunctionEpoxide hydrolase (EH) converts epoxides to trans-dihydrodiols which are excreted from the body. Thus, EH acts as a detoxification agent. Epoxides are formed from degradation of aromatic compounds[1]. DiseaseInhibitors of Mycobacterium tuberculosis EH such as urea derivatives, are used as anti-tuberculosis drugs. The valpromide inhibitor of EH is used as anti-epileptic drug. Soluble EH plays a role in several diseases including cardiovascular ones and is a drug target for their therapy [3]. RelevanceStructural highlights. 3D Structures of epoxide hydrolaseEpoxide hydrolase 3D structures
|
|
ReferencesReferences
- ↑ Biswal BK, Morisseau C, Garen G, Cherney MM, Garen C, Niu C, Hammock BD, James MN. The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor. J Mol Biol. 2008 Sep 12;381(4):897-912. Epub 2008 Jun 17. PMID:18585390 doi:10.1016/j.jmb.2008.06.030
- ↑ Arand M, Hallberg BM, Zou J, Bergfors T, Oesch F, van der Werf MJ, de Bont JA, Jones TA, Mowbray SL. Structure of Rhodococcus erythropolis limonene-1,2-epoxide hydrolase reveals a novel active site. EMBO J. 2003 Jun 2;22(11):2583-92. PMID:12773375 doi:http://dx.doi.org/10.1093/emboj/cdg275
- ↑ Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009 Oct;8(10):794-805. doi: 10.1038/nrd2875. PMID:19794443 doi:http://dx.doi.org/10.1038/nrd2875
- ↑ Oster L, Tapani S, Xue Y, Kack H. Successful generation of structural information for fragment-based drug discovery. Drug Discov Today. 2015 Apr 28. pii: S1359-6446(15)00154-3. doi:, 10.1016/j.drudis.2015.04.005. PMID:25931264 doi:http://dx.doi.org/10.1016/j.drudis.2015.04.005